BR112022005039A2 - Tratamento de hepatite alcoólica - Google Patents

Tratamento de hepatite alcoólica

Info

Publication number
BR112022005039A2
BR112022005039A2 BR112022005039A BR112022005039A BR112022005039A2 BR 112022005039 A2 BR112022005039 A2 BR 112022005039A2 BR 112022005039 A BR112022005039 A BR 112022005039A BR 112022005039 A BR112022005039 A BR 112022005039A BR 112022005039 A2 BR112022005039 A2 BR 112022005039A2
Authority
BR
Brazil
Prior art keywords
treatment
alcoholic hepatitis
methods
hepatitis
25hc3s
Prior art date
Application number
BR112022005039A
Other languages
English (en)
Portuguese (pt)
Inventor
E Brown James
Terrence Blaschke
Weiqi Lin
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durect Corp filed Critical Durect Corp
Publication of BR112022005039A2 publication Critical patent/BR112022005039A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022005039A 2019-09-30 2020-09-29 Tratamento de hepatite alcoólica BR112022005039A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962908465P 2019-09-30 2019-09-30
US201962933206P 2019-11-08 2019-11-08
US202063060564P 2020-08-03 2020-08-03
US202063081208P 2020-09-21 2020-09-21
PCT/US2020/053315 WO2021067297A1 (en) 2019-09-30 2020-09-29 Treatment of alcoholic hepatitis

Publications (1)

Publication Number Publication Date
BR112022005039A2 true BR112022005039A2 (pt) 2022-06-21

Family

ID=75336475

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005039A BR112022005039A2 (pt) 2019-09-30 2020-09-29 Tratamento de hepatite alcoólica

Country Status (13)

Country Link
US (2) US20220378802A1 (https=)
EP (1) EP4037650A4 (https=)
JP (1) JP7830313B2 (https=)
KR (1) KR20220075329A (https=)
CN (2) CN119868374A (https=)
AU (1) AU2020357818A1 (https=)
BR (1) BR112022005039A2 (https=)
CA (1) CA3155422A1 (https=)
IL (1) IL291287A (https=)
MX (1) MX2022003778A (https=)
PH (1) PH12022550698A1 (https=)
TW (1) TW202128184A (https=)
WO (1) WO2021067297A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3494125B1 (en) 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
EP4359420A4 (en) * 2021-06-25 2025-07-16 Durect Corp 25-HYDROXY-CHOLEST-5-EN-3-SULFATE CHOLINE, PROCESSES FOR THEIR PREPARATION, AND THEIR USES
EP4611888A1 (en) * 2022-10-31 2025-09-10 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists
WO2025101669A1 (en) * 2023-11-07 2025-05-15 Durect Corporation Treatment of alcohol-associated hepatitis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
US20150072962A1 (en) * 2012-04-12 2015-03-12 Virgini Commonwealth University Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosis
HRP20220112T1 (hr) * 2013-12-24 2022-04-15 Virginia Commonwealth University Upotreba oksidacijskog sulfata kolesterola (ocs) za liječenje akutne insuficijencije jetre
EP3494125B1 (en) * 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
EP3493810A4 (en) * 2016-08-02 2020-04-08 Durect Corporation COMPOSITIONS WITH OXYGENOUS CHOLESTERINSULFATE AND AT LEAST POLYALKYLENE GLYCOL, CARBOXYMETHYLCELLULOSE OR POLYOXYL GLYCERIDE

Also Published As

Publication number Publication date
JP7830313B2 (ja) 2026-03-16
TW202128184A (zh) 2021-08-01
CA3155422A1 (en) 2021-04-08
AU2020357818A1 (en) 2022-04-14
US20220378802A1 (en) 2022-12-01
CN119868374A (zh) 2025-04-25
PH12022550698A1 (en) 2023-04-03
JP2022549621A (ja) 2022-11-28
CN114555044B (zh) 2025-02-14
CN114555044A (zh) 2022-05-27
EP4037650A4 (en) 2023-10-18
EP4037650A1 (en) 2022-08-10
MX2022003778A (es) 2022-04-25
IL291287A (en) 2022-05-01
WO2021067297A1 (en) 2021-04-08
KR20220075329A (ko) 2022-06-08
US20260102410A1 (en) 2026-04-16

Similar Documents

Publication Publication Date Title
BR112022005039A2 (pt) Tratamento de hepatite alcoólica
EA201791675A1 (ru) Человеческие антитела к гликопротеину вируса эбола
MX2024000780A (es) Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon.
EA201890731A1 (ru) Модуляторы корового белка гепатита b
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
MY194764A (en) Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
BR112016016207A2 (pt) Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos
EA202190485A1 (ru) Соединения, модулирующие fxr (nr1h4)
EA201991862A1 (ru) Композиции и способы, предназначенные для лечения гемоглобинопатий
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
BR112016000975A8 (pt) esteróides neuroativos, composições os compreendendo e uso dos mesmos
EA201892480A1 (ru) Соединения, модулирующие fxr (nr1h4)
BR112022009317A2 (pt) Anticorpos de cd73 biparatópicos
BR112016029916A2 (pt) inibidores mnk e métodos correlatos
PH12018500233A1 (en) Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof
EP4691569A3 (en) Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
BR112016030686A2 (pt) anticorpos anti tau humanizados
CR20170080A (es) Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu abeta+inhibidor de a bace
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
BR112018073945A2 (pt) métodos para tratamento de miastenia grave generalizada refratária
JOP20210166A1 (ar) علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r
EA201791535A1 (ru) Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение
BR112015021483A2 (pt) arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer
EA201990988A1 (ru) Антитела против chikv и пути их применения
BR112024000744A2 (pt) Anticorpos de glicoprotéina spike anti-sars-cov-2 e fragmentos de ligação a antígeno

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122025021620-8 PROTOCOLO 870250091062 EM 06/10/2025 15:58.